# Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)

> **NCT07295223** · PHASE3 · RECRUITING · sponsor: **Instituto Mexicano del Seguro Social** · enrollment: 44 (estimated)

## Conditions studied

- Acute Myocardial Infarction With ST Elevation

## Interventions

- **DRUG:** Dapagliflozin 10 MG Oral Tablet
- **DRUG:** Semaglutide (Rybelsus®)

## Key facts

- **NCT ID:** NCT07295223
- **Lead sponsor:** Instituto Mexicano del Seguro Social
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-30
- **Primary completion:** 2026-08
- **Final completion:** 2026-09
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2026-01-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07295223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07295223, "Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07295223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*